stockrow
Friday 6 November 2026
Export SNN’s income statement to Excel — free account
Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
31.11
0.90
−2.81%
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Shares outstanding
Smith & Nephew SNATS, Inc.'s shares outstanding at the end of fiscal 2025 was $436.5M, unchanged from fiscal 2024. Over the past ten years it has ranged from $436.5M (fiscal 2025) to $449.5M (fiscal 2015) — the current reading is the lowest in ten years. Smith & Nephew SNATS, Inc. ranks 8th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $436.5M | (0.34%) |
| FY2024 | $438.0M | 0.34% |
| FY2023 | $436.5M | 0.00% |
| FY2022 | $436.5M | (0.57%) |
| FY2021 | $439.0M | 0.11% |
| FY2020 | $438.5M | 0.00% |
| FY2019 | $438.5M | 0.11% |
| FY2018 | $438.0M | 0.11% |
| FY2017 | $437.5M | (2.02%) |
| FY2016 | $446.5M | (0.67%) |
Against its own ten years
Low $436.5M
High $449.5M
Ten-year median
$438.0M
Current reading's percentile
27
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. | $449.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. compare | $136.0M |
| TXG 10x Genomics compare | $130.0M |
| PODD Insulet Corporation compare | $69.5M |
| GKOS Glaukos Corporation compare | $61.2M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement